Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biosecur Bioterror. 2010 Dec;8(4):357-63. doi: 10.1089/bsp.2010.0041.

The NIAID Radiation Countermeasures Program business model.

Author information

  • 1Radiation/Nuclear Medical Countermeasures Development Program, National Institute for Allergy and Infectious Diseases (NIAID)/NIH, 6610 Rockledge Drive, Bethesda, MD 20892, USA.

Abstract

The National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures Development Program has developed an integrated approach to providing the resources and expertise required for the research, discovery, and development of radiation/nuclear medical countermeasures (MCMs). These resources and services lower the opportunity costs and reduce the barriers to entry for companies interested in working in this area and accelerate translational progress by providing goal-oriented stewardship of promising projects. In many ways, the radiation countermeasures program functions as a "virtual pharmaceutical firm," coordinating the early and mid-stage development of a wide array of radiation/nuclear MCMs. This commentary describes the radiation countermeasures program and discusses a novel business model that has facilitated product development partnerships between the federal government and academic investigators and biopharmaceutical companies.

PMID:
21142762
[PubMed - indexed for MEDLINE]
PMCID:
PMC3011992
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk